Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline Review, H1 2015

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline Review, H1 2015', provides an overview of the Refractory Chronic Lymphocytic Leukemia (CLL)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia (CLL)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Refractory Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Refractory Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Refractory Chronic Lymphocytic Leukemia (CLL) Overview 8

Therapeutics Development 9

Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL)-Overview 9

Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL)-Comparative Analysis 10

Refractory Chronic Lymphocytic Leukemia (CLL)-Therapeutics under Development by Companies 11

Refractory Chronic Lymphocytic Leukemia (CLL)-Therapeutics under Investigation by Universities/Institutes 15

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Refractory Chronic Lymphocytic Leukemia (CLL)-Products under Development by Companies 19

Refractory Chronic Lymphocytic Leukemia (CLL)-Products under Investigation by Universities/Institutes 22

Refractory Chronic Lymphocytic Leukemia (CLL)-Companies Involved in Therapeutics Development 23

4SC AG 23

AbbVie Inc. 24

Astellas Pharma Inc. 25

Astex Pharmaceuticals, Inc. 26

AstraZeneca Plc 27

Boehringer Ingelheim GmbH 28

Bristol-Myers Squibb Company 29

Celgene Corporation 30

Cellular Biomedicine Group, Inc. 31

F. Hoffmann-La Roche Ltd. 32

Gilead Sciences, Inc. 33

GlaxoSmithKline Plc 34

ImmunoGen, Inc. 35

Immunomedics, Inc. 36

Infinity Pharmaceuticals, Inc. 37

Innate Pharma SA 38

Juno Therapeutics Inc. 39

Karyopharm Therapeutics, Inc. 40

Les Laboratoires Servier SAS 41

LFB S.A. 42

MedImmune, LLC 43

Millennium Pharmaceuticals, Inc. 44

MorphoSys AG 45

Neopharm Ltd. 46

Novartis AG 47

Ono Pharmaceutical Co., Ltd. 48

Portola Pharmaceuticals, Inc. 49

Sanofi 50

SpectraMab GmbH 51

TG Therapeutics, Inc. 52

Threshold Pharmaceuticals, Inc. 53

Refractory Chronic Lymphocytic Leukemia (CLL)-Therapeutics Assessment 54

Assessment by Monotherapy Products 54

Assessment by Combination Products 55

Assessment by Target 56

Assessment by Mechanism of Action 59

Assessment by Route of Administration 62

Assessment by Molecule Type 64

Drug Profiles 66

4SC-202-Drug Profile 66

ACP-196-Drug Profile 68

afuresertib hydrochloride-Drug Profile 70

AGS-67E-Drug Profile 72

AT-7519-Drug Profile 73

AZD-6738-Drug Profile 76

BI-836826-Drug Profile 77

BMS-986016-Drug Profile 78

buparlisib hydrochloride-Drug Profile 79

CBM-C19.1-Drug Profile 83

CBM-C20.1-Drug Profile 84

CC-122-Drug Profile 85

Cell Therapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia-Drug Profile 87

cerdulatinib-Drug Profile 88

duvelisib-Drug Profile 89

evofosfamide-Drug Profile 91

FBTA-05-Drug Profile 99

GS-9901-Drug Profile 100

IMGN-529-Drug Profile 101

IMMU-114-Drug Profile 103

IPH-2201-Drug Profile 104

JCAR-014-Drug Profile 106

JCAR-015-Drug Profile 107

MEDI-551-Drug Profile 109

MOR-208-Drug Profile 111

moxetumomab pasudotox-Drug Profile 113

nivolumab-Drug Profile 115

obinutuzumab-Drug Profile 121

pilaralisib-Drug Profile 124

S-055746-Drug Profile 127

selinexor-Drug Profile 128

spebrutinib besylate-Drug Profile 133

TAK-659-Drug Profile 135

TGR-1202-Drug Profile 136

tisagenlecleucel-T-Drug Profile 138

trametinib dimethyl sulfoxide-Drug Profile 140

Triplebody 19x16x19-Drug Profile 143

ublituximab-Drug Profile 144

ublituximab [INN] + TGR-1202-Drug Profile 146

UC-961-Drug Profile 147

ulocuplumab-Drug Profile 148

urelumab-Drug Profile 150

venetoclax-Drug Profile 152

vismodegib-Drug Profile 155

Refractory Chronic Lymphocytic Leukemia (CLL)-Recent Pipeline Updates 158

Refractory Chronic Lymphocytic Leukemia (CLL)-Dormant Projects 233

Refractory Chronic Lymphocytic Leukemia (CLL)-Discontinued Products 235

Refractory Chronic Lymphocytic Leukemia (CLL)-Product Development Milestones 236

Featured News & Press Releases 236

Appendix 245

Methodology 245

Coverage 245

Secondary Research 245

Primary Research 245

Expert Panel Validation 245

Contact Us 245

Disclaimer 246

List of Tables

Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H1 2015 12

Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL)-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 15

Number of Products under Development by Companies, H1 2015 (Contd..1) 16

Number of Products under Development by Companies, H1 2015 (Contd..2) 17

Number of Products under Investigation by Universities/Institutes, H1 2015 18

Comparative Analysis by Late Stage Development, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Development, H1 2015 21

Products under Development by Companies, H1 2015 22

Products under Development by Companies, H1 2015 (Contd..1) 23

Products under Development by Companies, H1 2015 (Contd..2) 24

Products under Investigation by Universities/Institutes, H1 2015 25

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by 4SC AG, H1 2015 26

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by AbbVie Inc., H1 2015 27

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by Astellas Pharma Inc., H1 2015 28

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 29

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by AstraZeneca Plc, H1 2015 30

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by Boehringer Ingelheim GmbH, H1 2015 31

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by Bristol-Myers Squibb Company, H1 2015 32

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by Celgene Corporation, H1 2015 33

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by Cellular Biomedicine Group, Inc., H1 2015 34

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 35

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by Gilead Sciences, Inc., H1 2015 36

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by GlaxoSmithKline Plc, H1 2015 37

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by ImmunoGen, Inc., H1 2015 38

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by Immunomedics, Inc., H1 2015 39

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by Infinity Pharmaceuticals, Inc., H1 2015 40

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by Innate Pharma SA, H1 2015 41

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by Juno Therapeutics Inc., H1 2015 42

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 43

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by Les Laboratoires Servier SAS, H1 2015 44

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by LFB S.A., H1 2015 45

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by MedImmune, LLC, H1 2015 46

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 47

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by MorphoSys AG, H1 2015 48

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by Neopharm Ltd., H1 2015 49

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by Novartis AG, H1 2015 50

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 51

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by Portola Pharmaceuticals, Inc., H1 2015 52

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by Sanofi, H1 2015 53

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by SpectraMab GmbH, H1 2015 54

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by TG Therapeutics, Inc., H1 2015 55

Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 56

Assessment by Monotherapy Products, H1 2015 57

Assessment by Combination Products, H1 2015 58

Number of Products by Stage and Target, H1 2015 60

Number of Products by Stage and Mechanism of Action, H1 2015 63

Number of Products by Stage and Route of Administration, H1 2015 66

Number of Products by Stage and Molecule Type, H1 2015 68

Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics-Recent Pipeline Updates, H1 2015 161

Refractory Chronic Lymphocytic Leukemia (CLL)-Dormant Projects, H1 2015 236

Refractory Chronic Lymphocytic Leukemia (CLL)-Dormant Projects (Contd..1), H1 2015 237

Refractory Chronic Lymphocytic Leukemia (CLL)-Discontinued Products, H1 2015 238

List of Figures

Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H1 2015 12

Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL)-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 20

Assessment by Monotherapy Products, H1 2015 57

Number of Products by Top 10 Targets, H1 2015 59

Number of Products by Stage and Top 10 Targets, H1 2015 59

Number of Products by Top 10 Mechanism of Actions, H1 2015 62

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 62

Number of Products by Top 10 Routes of Administration, H1 2015 65

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 65

Number of Products by Top 10 Molecule Types, H1 2015 67

Number of Products by Stage and Top 10 Molecule Types, H1 2015 67

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

AbbVie Inc.

Astellas Pharma Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca Plc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corporation

Cellular Biomedicine Group, Inc.

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

GlaxoSmithKline Plc

ImmunoGen, Inc.

Immunomedics, Inc.

Infinity Pharmaceuticals, Inc.

Innate Pharma SA

Juno Therapeutics Inc.

Karyopharm Therapeutics, Inc.

Les Laboratoires Servier SAS

LFB S.A.

MedImmune, LLC

Millennium Pharmaceuticals, Inc.

MorphoSys AG

Neopharm Ltd.

Novartis AG

Ono Pharmaceutical Co., Ltd.

Portola Pharmaceuticals, Inc.

Sanofi

SpectraMab GmbH

TG Therapeutics, Inc.

Threshold Pharmaceuticals, Inc.

Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutic Products under Development, Key Players in Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics, Refractory Chronic Lymphocytic Leukemia (CLL) Pipeline Overview, Refractory Chronic Lymphocytic Leukemia (CLL) Pipeline, Refractory Chronic Lymphocytic Leukemia (CLL) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com